Sandoz Brief Addresses US Supreme Court in Case Against Amgen
Multiple Challenges Predicted for Biosimilars in 2017
European Drug Agency's Move Out of London, Spurred By Brexit, Could Disrupt Pipeline
Nominee for FDA Commissioner Vows to Strike Balance Before Senate Panel
Biologics Superior for Relief of IBD Symptoms and Maintenance of Intestinal Health
New Research Compares Effectiveness, Safety of Branded and Biosimilar Filgrastim
Indian Generic Pharma Companies in a Race to Develop Biosimilars
MS Drugs Price Comparison Called "Misleading and Oversimplified"
Rituxan Given Breakthrough Therapy Designation for Pemphigus Vulgaris
New Drug Approved for MS, First With PPMS Indication
Infographic: A Guide to Briefs in the Amgen vs Sandoz Supreme Court Case
Dupilumab, a Biologic Treatment for Eczema, Approved by FDA
NHS May Use More "Stick" Than "Carrot" to Ensure Prescribing of Cheaper Biosimilars
Policy Briefing Calls for More Efficient Biosimilar Approval Process
Amgen Gains EC Approval for Biosimilar to Adalimumab
Payer Cost Savings From Filgrastim Biosimilars Could Reach $2 Million Annually
New Lawsuit Concerning Insulin Price-Fixing Filed in Federal Court
Amgen Files for EU Approval of Its Herceptin Biosimilar for Breast Cancer
Infographic: Biosimilar Substitution Laws By State
Congressional Hearing on FDA User Fees Tackles Issues Affecting Biosimilar Approvals
Trump Administration Budget Blueprint Comes With Major Cuts to Health and Science
Greater Transparency at FDA Would Bring More Biosimilars to Market, Experts Say
Dr Scott Gottlieb, Trump's FDA Pick, a Consistent Supporter of Biosimilar Innovation
Mylan's Settlement With Genentech and Roche Opens US Market for Trastuzumab Biosimilar
European Industry Groups Urge Caution on Biosimilar Switching
Merck KGaA Close to Selling Biosimilars Division to Undisclosed Buyer
Amgen Lawsuit Against Coherus Alleges Misappropriation of Neulasta Trade Secrets
Siliq Approved Without a Suffix
Sandoz Releases Efficacy Data for Its Humira Biosimilar
New Delhi High Court Allows Marketing of Biocon-Mylan Biosimilar of Trastuzumab
